ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join us for the ACC Rockies Chapter Meeting from August 5-7, 2022 at the Hyatt Centric in Park City, Utah. For more information and to register, please visit: https://cvent.me/zaKr2z
Latest in Cardiology from ACC.org
- Five-Tier Comparison of Heart Transplant Programs: Clarity or Confusion?How useful is the 5-tier Scientific Registry of Transplant Recipients (SRTR) ranking for heart transplant programs?
- Initiation of Statins for Primary Prevention in HFpEFIs statin use associated with a lower risk of mortality and major adverse cardiovascular events (MACE) in patients who have heart failure with preserved ejection fraction (HFpEF)?
- ARISE-HF Primary Results: Selective Aldose Reductase Inhibitor For Diabetic CardiomyopathyIn this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy.
- Reinterventions After TAVR or SAVR for Severe Aortic StenosisWhat is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR)?
- Efficacy and Safety of Dapagliflozin in Acute Heart FailureThe goal of the DICTATE-AHF trial was to determine the efficacy and safety of adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin to intravenous (IV) loop diuretic therapy in patients hospitalized with acute decompensated heart failure (ADHF).